Preclinical tests showed that the company's signature therapy, Telomir-1, appeared to address insulin resistance and achieving reversal to near pre-diabetic levels.
What is covered in the Full Insight:
Introduction to Telomir Pharmaceuticals
Telomir-1 Preclinical Results
Impact on Type 2 Diabetes
Future Research Directions
Financial and Market Analysis
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.